Conde Nast Portfolio shines a light on Questcor

Writing for Conde Nast's Portfolio.com (Drug Money), Russ Mitchell tells the story of Questcor's almost 20-fold boost in the price of H.P. Achtar Gel, a treatment for infantile spasms. The article does a nice job recounting the story behind this move and the impact it's having on physicians and patients. I've written a fair bit on this topic (see, for example Abusing the Orphan Drug law to rip off customers) and other bloggers have posted more in-depth pieces. Unfortunately until now the few pieces in the mainstream media have botched the story. The New York Times, for its part, decided to blame the price increase on PBMs like Express Scripts, which is a complete joke. (See New York Times is 7+ months late with H.P. Acthar Gel story and still misses the point.)Thanks, Russ for getting it right.